“扭亏”上岸,百济一季度营收80亿,新“一哥”诞生?

医药经济报
08 May

泽布替尼狂揽56亿夺美国市场份额第一百济神州2025年一季报业绩亮眼,自研产品泽布替尼和替雷利珠单抗以及安进授权产品的销售额增加,被视为业绩大涨的直接原因。特别是泽布替尼,作为BTK抑制剂,其在全球70个市场获批,2024年销售额突破20亿美元大关,2025年第一季度全球销售额达到56.92亿元,同比增长63.7%。按地区收入来看,泽布替尼在美国市场的表现尤为突出。百济神州的新闻稿中提到,在...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10